| 80.805 -0.275 (-0.34%) | 07-14 12:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 97.9 | 1-year : | 101.83 |
| Resists | First : | 83.82 | Second : | 87.19 |
| Pivot price | 83.54  |
|||
| Supports | First : | 78.37 | Second : | 65.21 |
| MAs | MA(5) : | 82.54 |
MA(20) : | 82.95 |
| MA(100) : | 78.98 |
MA(250) : | 82.39 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 27.7 |
D(3) : | 43.2 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 99.5 | Low : | 62.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANIP ] has closed above bottom band by 7.8%. Bollinger Bands are 18.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 82.91 - 83.49 | 83.49 - 83.93 |
| Low: | 78.54 - 79.32 | 79.32 - 79.92 |
| Close: | 80 - 81.06 | 81.06 - 81.87 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Tue, 14 Jul 2026
symbol__ Stock Quote Price and Forecast - CNN
Mon, 13 Jul 2026
ANI Pharmaceuticals reports positive uveitis trial results - grafa.com
Mon, 13 Jul 2026
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant - Proactive financial news
Mon, 13 Jul 2026
Eye implant trial from ANI Pharmaceuticals improves vision and retinal thickness at 6 months - Stock Titan
Sun, 12 Jul 2026
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run - The Motley Fool
Sat, 11 Jul 2026
ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 23 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 110.2 (%) |
| Shares Short | 3,440 (K) |
| Shares Short P.Month | 3,320 (K) |
| EPS | 3.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.34 |
| Profit Margin | 9.9 % |
| Operating Margin | 16.2 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 18.3 % |
| Qtrly Rev. Growth | 20.5 % |
| Gross Profit (p.s.) | 24.71 |
| Sales Per Share | 40.63 |
| EBITDA (p.s.) | 8.68 |
| Qtrly Earnings Growth | 86 % |
| Operating Cash Flow | 209 (M) |
| Levered Free Cash Flow | 140 (M) |
| PE Ratio | 20.71 |
| PEG Ratio | 0 |
| Price to Book value | 3.07 |
| Price to Sales | 1.99 |
| Price to Cash Flow | 8.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|